Gregory Sergeant1, Freddy Penninckx, Baki Topal. 1. Department of Abdominal Surgery, University Hospitals Gasthuisberg, Leuven, Belgium. gregory.sergeant@uz.kuleuven.ac.be
Abstract
BACKGROUND: Twenty percent to 40% of patients with node-negative colorectal cancer die of metastatic disease. Detection of cancer cell dissemination has been proposed as a tool to select patients at highest risk for recurrence. In this review, we summarize the evidence for detection with quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assays of circulating tumor cells (CTCs) in peripheral blood of colorectal cancer patients. MATERIALS AND METHODS: Pubmed and Embase were systematically searched for all English publications relevant to circulating cancer cells, peripheral blood, quantitative RT-PCR (q-RT-PCR), and colorectal cancer. Cross-references and the "related articles" function were used to broaden the search. Manuscripts reporting on the results of nonquantitative RT-PCR assays were excluded. The study methodology, CTCs detection rates in peripheral blood, and prognostic value were reviewed. RESULTS: Twelve manuscripts on qRT-PCR were retrieved. Stage dependence was found for detection of CTCs in four of 10 studies. From univariate analysis performed for disease-free survival and overall survival in 4 of 12 studies, there was evidence (P < 0.05) for an effect of the detection of CTCs with qRT-PCR. None of the included trials identified detection of CTCs in peripheral blood as an independent predictor of survival. CONCLUSION: Quantification of CTCs in peripheral blood holds promise in predicting stage and outcome in colorectal cancer patients. At present, evidence from the literature is too scarce to integrate quantitative RT-PCR assays to detect CTCs into the management of colorectal cancer.
BACKGROUND: Twenty percent to 40% of patients with node-negative colorectal cancer die of metastatic disease. Detection of cancer cell dissemination has been proposed as a tool to select patients at highest risk for recurrence. In this review, we summarize the evidence for detection with quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) assays of circulating tumor cells (CTCs) in peripheral blood of colorectal cancerpatients. MATERIALS AND METHODS: Pubmed and Embase were systematically searched for all English publications relevant to circulating cancer cells, peripheral blood, quantitative RT-PCR (q-RT-PCR), and colorectal cancer. Cross-references and the "related articles" function were used to broaden the search. Manuscripts reporting on the results of nonquantitative RT-PCR assays were excluded. The study methodology, CTCs detection rates in peripheral blood, and prognostic value were reviewed. RESULTS: Twelve manuscripts on qRT-PCR were retrieved. Stage dependence was found for detection of CTCs in four of 10 studies. From univariate analysis performed for disease-free survival and overall survival in 4 of 12 studies, there was evidence (P < 0.05) for an effect of the detection of CTCs with qRT-PCR. None of the included trials identified detection of CTCs in peripheral blood as an independent predictor of survival. CONCLUSION: Quantification of CTCs in peripheral blood holds promise in predicting stage and outcome in colorectal cancerpatients. At present, evidence from the literature is too scarce to integrate quantitative RT-PCR assays to detect CTCs into the management of colorectal cancer.
Authors: F Jeroen Vogelaar; Wilma E Mesker; Arjen M Rijken; Gaby W van Pelt; Antonia M van Leeuwen; Hans J Tanke; Rob A Tollenaar; Gerrit J Liefers Journal: BMC Cancer Date: 2010-04-20 Impact factor: 4.430
Authors: Jennifer E Hardingham; Phulwinder Grover; Marnie Winter; Peter J Hewett; Timothy J Price; Benjamin Thierry Journal: Mol Med Date: 2015-10-27 Impact factor: 6.354
Authors: Gregory Sergeant; Tania Roskams; Jos van Pelt; François Houtmeyers; Raymond Aerts; Baki Topal Journal: BMC Cancer Date: 2011-01-31 Impact factor: 4.430